Entering text into the input field will update the search result below

Progenics Pharmaceuticals' (PGNX) CEO Mark Baker on Q4 2017 Results - Earnings Call Transcript

SA Transcripts profile picture
SA Transcripts

Progenics Pharmaceuticals Inc. (NASDAQ:PGNX) Q4 2017 Results Earnings Conference Call March 8, 2018 8:30 AM ET


Melissa Downs - Senior Manager, IR

Mark Baker - CEO

Pat Fabbio - SVP and CFO


Tim Chiang - BTIG

Mara Goldstein - Cantor Fitzgerald & Co.

Jonathan Aschoff - National Securities Corporation

Chad Messer - Needham & Company


Good day ladies and gentlemen and welcome to the Progenics Fourth Quarter and Year End 2017 Earnings Conference Call. At this time all participants are in a listen-only mode. Later, we will conduct a question-and-answer session and instructions will follow at that time. [Operator Instructions] As a reminder, this conference is being recorded.

I would now like to hand the floor over to Melissa Downs, Senior Manager of Investor Relations. Please go ahead.

Melissa Downs

Thank you, Karen. On behalf of Progenics management team, thank you for joining our conference call to review our fourth quarter and full year 2017 financial results and provide a business update. Joining the call today are Mark Baker, Chief Executive Officer; and Pat Fabbio, Senior Vice President and Chief Financial Officer.

Before we begin, I'll remind you that remarks made on this call that are not historical in nature may be forward-looking statements and are subject to a number of risks and uncertainties. Our actual results may differ materially. Such remarks may include, but are not limited to, those involving regulatory actions, clinical development, and other matters related to our prostate cancer pipeline, AZEDRA, RELISTOR, and our other product candidates; our business and commercialization strategies and expectations of future growth; revenues and assessments of our competitive position.

Please see our most recent forms 10-Q and 10-K, which we'll -- we will be filing later today and other filings with the U.S. Securities and Exchange Commission for additional information on the

Recommended For You


To report an error in this transcript, .Contact us to add your company to our coverage or use transcripts in your business. Learn more about Seeking Alpha transcripts here. Your feedback matters to us!

More on PGNX

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.